Yazar "Albayrak, Murat" seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • [ X ]
    Öğe
    Association of Thrombin-Activatable Fibrinolysis Inhibitor with Acute Pulmonary Embolism
    (Georg Thieme Verlag Kg, 2021) Yıldız, Abdulkerim; Katar, Didem; Özden Soydaş, Ayşe; Albayrak, Murat
    Background Thrombin-activatable fibrinolysis inhibitor (TAFI) inhibits fibrinolysis and high levels may have an association with thrombosis. The aim of the current study was to investigate the association of TAFI antigen levels with pulmonary thromboembolism (PTE). Patients and Methods A case-control study was conducted with 29 patients with PTE and 17 age- and gender-matched control individuals. Plasma levels of TAFI were measured at the time of diagnosis, then at 3 and 6 months after the event. Results Initial TAFI levels (%) were higher in patients with PTE than in the control group Initial TAFI levels (%) were higher in patients with PTE than in the control group (190,0 [65,0-250,0] vs 133,0 [83,0-153,0]; p =0.003). TAFI levels significantly decreased at the third and sixth months after initial diagnosis ( p <0.05). The percentage reductions in TAFI levels were 12 and 36.8% at 3 and 6 months, respectively. The Odss ratio (OR) of TAFI level for PTE was found to be 1.024 (95% CI: 1.007-1.040; p =0.005). There was no significant correlation of initial TAFI levels with age, gender, smoking status, history of thrombosis, pulmonary artery pressure, and D-dimer levels ( p >0.05). In the sixth month of treatment, patients with residual thrombosis were seen to have similar baseline levels and reductions of TAFI as patients without residual thrombosis ( p >0.05). Conclusion The result of this study suggests that high TAFI levels may have a role in the occurrence of PTE without impact on treatment outcome.
  • Küçük Resim
    Öğe
    Co-occurence of follicular lymphoma and Langerhans cell histiocytosis with primary parotid gland involvement: a case report
    (Elsevier Editora Ltda, 2021) Albayrak, Aynur; Yıldız, Abdulkerim; Albayrak, Murat; Uçaryılmaz Özhamam, Esra; Maral, Senem
    Follicular lymphoma (FL) is one of the most common types ofNon-Hodgkin Lymphoma (NHL) which originates from B-cells.1Generally it has an indolent clinical course, althoughhistological transformation to aggressive lymphoma mayoccur in 25-35 % of cases, and therafter the prognosis hasbeen reported to be poor. Transformation to histiocytic sar-coma may also be seen but very rarely
  • [ X ]
    Öğe
    The Charlson Comorbidity Index Predicts Poor Prognosis in Elderly AML Patients
    (AKAD DOKTORLAR YAYINEVI, 2023) Tığlıoğlu, Mesut; Albayrak, Murat; Tığlıoğlu, Pınar; Yıldız, Abdulkerim; Doğan, Servihan; Afacan Öztürk, Hacer Berna; Maral, Senem; Sağlam, Buğra; Aras, Merih Reis; Dilek, İmdat
    Acute myeloid leukemia (AML) is the most common type of acute leukemia in adults and patients older than 65 years have a poor prognosis. Patient-related factors, such as comorbid conditions that affect performance status, and insufficient organ functions, explain why elderly patients have a worse prognosis. The Charlson Comorbidity Index (CCI), is used to predict prognosis according to comorbidities. This retrospective study was conducted on patients diagnosed with AML between 2010 and 2019. Patients >60 years were included. Demographic information, comorbidities, CCI, ECOG ( Eastern Cooperative Oncology Group) score, cytogenetic characteristics, treatment regimens, treatment response, follow-up periods were recorded for all patients. Evaluation was made of a total of 82 patients with a mean age of 71.18 ± 7.67. The median follow-up was 6.7 months. The median number of comorbidities was 1 [0.0-4.0] with the median CCI score of 3 [2.0-6.0]. Median overall survival (OS) was 7.0 months [3.1-10.8] and PFS was 6.8 months [3.6-10.0]. As the median CCI score was 3, patients were divided into two groups as CCI > 3 and CCI ? 3. Age, gender, ECOG, cytogenetic risk profile, first-line treatment and CR1 achievement status were all similar in both groups (p > 0.05). Patients with CCI > 3 had significantly shorter OS than patients with CCI ? 3 (3.6 months [0.3-29.3] vs 8.6 months [0.2-60.2], p= 0.049). The results of the current study demonstrated that CCI, can be used as a prognostic index in elderly patients with AML independently of other patient and disease-related characteristics.